RxDoctor Payments Data

Florence Wooten, MD

Ophthalmology · Houston, TXNPI 1710932827

Payments from drug & device makers

$981in general payments, 2019–2025

Across 44 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$394
  • Alcon$222
  • Novartis$132
  • Aerie Pharmaceuticals, Inc.$93
  • Eyevance Pharmaceuticals LLC$37
  • Sun Pharmaceutical Industries Inc.$32
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$92494%
  • Education$586%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$981 in reported general payments places this provider in the 35th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$42,695
Medicare patients
176
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine100$110,344
RhopressaNetarsudil Mesylate91$56,115
Cyclosporine37$24,853
CombiganBrimonidine Tartrate/Timolol56$18,065
Travoprost56$16,722
LumiganBimatoprost24$16,335
Timolol Maleate193$12,392
Latanoprost891$10,128
Bromfenac Sodium57$8,145
Loteprednol Etabonate42$8,057
Brinzolamide47$7,902
VyzultaLatanoprostene Bunod16$6,852
Dorzolamide Hcl237$6,071
SimbrinzaBrinzolamide/Brimonidine Tart19$6,059
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$5,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$394$144,744180 claims
Aerie Pharmaceuticals, Inc.Rhopressa$93$56,11591 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$21$8,05742 claims
Bausch & Lomb Americas Inc.Vyzulta$18$6,85216 claims
AlconSimbrinza$222$6,05919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →